ImmuCell Corporation (ICCC)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
ImmuCell Corporation (ICCC) trades at $10.12 with AI Score 40/100 (Grade C). ImmuCell Corporation focuses on developing, manufacturing, and marketing animal health products for the dairy and beef cattle industries. Market cap: $91.56M, Sector: Healthcare.
Price live · AI analysis from May 8, 2026Analyst Coverage for ICCC: ICCC does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates ICCC against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
ICCC: 3/7 perspectives are bullish. Dominant signal: Ken Griffin bearish.
How is this calculated? →ImmuCell Corporation (ICCC) Healthcare & Pipeline Overview
ImmuCell Corporation, an animal health company, specializes in developing and marketing products to enhance the health and productivity of dairy and beef cattle, primarily through its First Defense scours prevention product. The company operates within the competitive biotechnology sector, focusing on animal health solutions.
What Is the Investment Thesis for ICCC?
ImmuCell Corporation presents a focused investment opportunity within the animal health sector, specifically targeting the dairy and beef cattle markets. With a market capitalization of $91.56M, the company's growth potential is tied to the increasing demand for preventative animal health solutions. The success of First Defense and the potential approval and market penetration of Re-Tain are key value drivers. However, the company's negative profit margin of -3.8% indicates a need for improved cost management and revenue growth. Investors should monitor the progress of Re-Tain's development and regulatory approval, as well as the company's ability to expand its market share and improve profitability.
Based on FMP financials and quantitative analysis
ICCC Key Highlights
- Market capitalization of $91.56M indicates a small-cap company with potential for growth.
- Gross margin of 41.4% reflects the company's ability to generate revenue above the cost of goods sold.
- Beta of 0.31 suggests lower volatility compared to the overall market.
- Focus on preventative animal health solutions aligns with the increasing demand for proactive veterinary care.
- Development of Re-Tain represents a potential growth catalyst in the treatment of subclinical mastitis.
Who Are ICCC's Competitors?
ICCC is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| VET Vermilion Energy Inc. | $8.77 | -2.50% | $1.34B | 51 |
| MRK Merck & Co., Inc. | $126.78 | -2.15% | $313.12B | 83 |
| SNDX Syndax Pharmaceuticals, Inc. | $22.11 | +1.33% | $1.96B | 79 |
| ANAB AnaptysBio, Inc. | $63.69 | +0.43% | $2.75B | 79 |
| CGEN Compugen Ltd. | $2.37 | +3.73% | $223.62M | 76 |
| XFOR X4 Pharmaceuticals, Inc. | $4.09 | -0.86% | $386.20M | 76 |
| DAWN Day One Biopharmaceuticals, Inc. | $21.53 | +0.00% | $2.22B | 68 |
| GLUE Monte Rosa Therapeutics, Inc. | $23.06 | -4.75% | $1.50B | 68 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are ICCC's Key Strengths?
- Specialized expertise in dairy and beef cattle health.
- Established product with First Defense.
- Proprietary manufacturing processes.
- Distribution network in place.
What Are ICCC's Weaknesses?
- Small market capitalization.
- Negative profit margin.
- Limited product diversification.
- Reliance on a few key products.
What Could Drive ICCC Stock Higher?
- Regulatory decision on Re-Tain approval for treating subclinical mastitis.
- Expansion of First Defense product line into new markets.
- Strategic partnerships with animal health distributors.
What Are the Key Risks for ICCC?
- Negative return on equity (-1.9%) — the business is not currently generating profit on shareholder capital.
- Failure to obtain regulatory approval for Re-Tain.
- Increased competition from larger animal health companies.
- Fluctuations in commodity prices affecting dairy and beef industries.
- Dependence on the success of First Defense product line.
What Are the Growth Opportunities for ICCC?
- Expansion of First Defense Product Line: ImmuCell can expand its First Defense product line by developing new formulations tailored to specific regional needs or disease challenges. The global market for livestock vaccines and preventatives is projected to reach $10 billion by 2028, offering a significant opportunity for ImmuCell to capture a larger market share through targeted product innovation and marketing efforts. This expansion can be achieved within the next 2-3 years.
- Regulatory Approval and Launch of Re-Tain: The successful regulatory approval and commercial launch of Re-Tain, its Nisin-based intramammary treatment for subclinical mastitis, represents a significant growth opportunity. Mastitis is a prevalent and costly disease in dairy cows, and an effective treatment could generate substantial revenue. The timeline for approval and launch is dependent on regulatory processes, but could potentially contribute to revenue growth within the next 3-5 years.
- Geographic Expansion into International Markets: ImmuCell currently focuses on the US market. Expanding into international markets, particularly in regions with large dairy and beef cattle populations, presents a substantial growth opportunity. Markets like Europe, South America, and Asia offer significant potential for increased sales of First Defense and other products. This expansion could be phased in over the next 5 years.
- Strategic Partnerships and Distribution Agreements: Forming strategic partnerships with animal health distributors and veterinary service providers can enhance ImmuCell's market reach and penetration. Collaborations with established players in the industry can provide access to new customer segments and distribution channels. These partnerships can be established within the next 1-2 years, leading to increased sales and market share.
- Development of New Animal Health Products: Investing in research and development to create new animal health products targeting other common diseases and conditions in dairy and beef cattle can diversify ImmuCell's product portfolio and revenue streams. This could include products for respiratory diseases, metabolic disorders, or reproductive health. The timeline for new product development and launch is typically 3-5 years, but can provide long-term growth potential.
What Opportunities Does ICCC Have?
- Regulatory approval and launch of Re-Tain.
- Expansion into international markets.
- Strategic partnerships with distributors.
- Development of new animal health products.
What Threats Does ICCC Face?
- Competition from larger animal health companies.
- Regulatory hurdles for new products.
- Fluctuations in commodity prices affecting dairy and beef industries.
- Disease outbreaks impacting livestock populations.
What Are ICCC's Competitive Advantages?
- Specialized focus on dairy and beef cattle health.
- Established product line with First Defense.
- Proprietary formulations and manufacturing processes.
- Distribution network through animal health distributors.
What Does ICCC Do?
ImmuCell Corporation, founded in 1982 and headquartered in Portland, Maine, is dedicated to improving the health and productivity of dairy and beef cattle. The company develops, manufactures, and markets animal health products both in the United States and internationally. Its flagship product, First Defense, is an orally delivered solution designed to prevent scours in newborn dairy and beef calves, a common and costly ailment in the industry. ImmuCell also offers Tri-Shield First Defense, which provides passive antibody protection against E. coli, coronavirus, and rotavirus. Additionally, the company provides the California Mastitis Test, a diagnostic tool used to detect somatic cell counts in milk, aiding in the identification of mastitis in dairy cows. ImmuCell continues to innovate, with products like Dual-Force First Defense, incorporating whey protein concentrate for nutritional supplementation, and the development of Re-Tain, a Nisin-based intramammary treatment for subclinical mastitis in lactating dairy cows. These products are distributed through animal health distributors, reaching farmers and veterinarians across the country and beyond.
What Products and Services Does ICCC Offer?
- Develops and manufactures animal health products.
- Markets products for dairy and beef cattle.
- Offers First Defense for scours prevention in newborn calves.
- Provides Tri-Shield First Defense for protection against E. coli, coronavirus, and rotavirus.
- Sells California Mastitis Test for detecting somatic cell counts in milk.
- Develops Re-Tain for treating subclinical mastitis in lactating dairy cows.
How Does ICCC Make Money?
- Develops and manufactures animal health products for dairy and beef cattle.
- Sells products through animal health distributors.
- Generates revenue from the sale of First Defense and other preventative and treatment products.
What Industry Does ICCC Operate In?
ImmuCell Corporation operates within the animal health industry, a sector driven by the increasing demand for livestock productivity and health. The market is characterized by a mix of large pharmaceutical companies and smaller, specialized players like ImmuCell. Key trends include the growing emphasis on preventative care, the rise of precision livestock farming, and the increasing adoption of animal health technologies. Competition includes companies offering similar scours prevention and mastitis treatment products. ImmuCell's focus on dairy and beef cattle health positions it within a specific niche of this broader market.
Who Are ICCC's Key Customers?
- Dairy farmers
- Beef cattle ranchers
- Veterinarians
- Animal health distributors
FY2026 estForward Outlook
Wall Street analysts project ImmuCell Corporation revenue of about $15.1M for fiscal 2026, with EPS near $-0.24.
F-Score 6/9Financial Health
ImmuCell Corporation's Piotroski F-Score is 6/9, a 9-point checklist of profitability, leverage and efficiency — a middling fundamental profile. Its Altman Z-Score of 4.27 places it in the safe zone, indicating low near-term bankruptcy risk.
ROE -2%Key Financial Metrics
Return on equity for ImmuCell Corporation stands at -1.9%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -1.2%, showing how much profit it generates from its asset base. Its free cash flow yield is 3.7%, a gauge of the cash the business throws off relative to its market value. A current ratio of 4.82 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -0.6%, the inverse of the P/E and a quick read on earnings relative to price.
ImmuCell Corporation (ICCC) Valuation Context
Valued at $91.56M, ICCC is classified as a micro-cap stock. Relative to its peer group, ICCC's quantitative score of 40/100 is below the peer average of 74/100.
Company Profile
ImmuCell Corporation operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Portland, US. The company is led by CEO F. Olivier Te Boekhorst. ICCC has traded publicly since 1987.
ICCC Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2025
Bull Case vs Bear Case
Bull Case
- ImmuCell's recent insider buying signals strong confidence from those closest to the company, suggesting potential upside.
- The buzz in trading communities indicates growing optimism about ICCC's long-term prospects, fueled by recent product advancements.
- The market seems to be viewing ICCC as a leader in its niche, which could lead to increased investment and valuation.
- Positive community sentiment reflects belief in ImmuCell's ability to capitalize on market opportunities, driving further growth.
Bear Case
- Some insiders might be selling shares to diversify their holdings, which can create short-term selling pressure.
- Community sentiment can be fickle, and recent hype around ICCC might be unsustainable in the face of broader market volatility.
- Market perception can quickly shift if competitors emerge or if ICCC faces regulatory hurdles.
- Despite positive sentiment, concerns linger about the company's ability to scale production to meet growing demand, potentially limiting revenue growth.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · February 2026
ICCC Latest News
-
Earnings Scheduled For May 14, 2026
benzinga · May 14, 2026
-
Earnings Scheduled For November 13, 2025
benzinga · Nov 13, 2025
-
Stocks That Hit 52-Week Lows On Thursday
benzinga · Mar 16, 2023
ICCC Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for ICCC.
Price Targets
Wall Street price target analysis for ICCC.
ICCC MoonshotScore
What does this score mean?
The MoonshotScore rates ICCC's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: F. Olivier Te Boekhorst
CEO
F. Olivier Te Boekhorst serves as the Chief Executive Officer of ImmuCell Corporation. His background includes extensive experience in the animal health industry, with a focus on strategic leadership and business development. He has held various leadership positions in both domestic and international markets, bringing a global perspective to ImmuCell's operations. His expertise spans product development, marketing, and sales, contributing to his comprehensive understanding of the animal health landscape. He is responsible for managing 69 employees.
Track Record: Under F. Olivier Te Boekhorst's leadership, ImmuCell has focused on expanding its product line and market reach, particularly with its First Defense product. A key strategic decision has been the continued investment in the development of Re-Tain, a potential new treatment for mastitis. He has overseen efforts to strengthen the company's distribution network and explore new market opportunities.
ICCC Healthcare Stock FAQ
What does ImmuCell Corporation do?
ImmuCell Corporation is an animal health company focused on developing, manufacturing, and marketing products that improve the health and productivity of dairy and beef cattle. Their primary product, First Defense, is an orally administered solution that prevents scours in newborn calves. The company also develops treatments for mastitis and other common diseases affecting livestock. ImmuCell sells its products through a network of animal health distributors, targeting farmers and veterinarians in the United States and internationally. Their business model centers on providing preventative and therapeutic solutions to enhance animal welfare and farm profitability.
What do analysts say about ICCC stock?
Analyst coverage of ImmuCell Corporation (ICCC) is limited, reflecting its small-cap status. Key valuation metrics to consider include the company's market capitalization relative to its revenue and earnings potential. Growth considerations center on the successful commercialization of Re-Tain and the expansion of the First Defense product line. Investors should monitor the company's financial performance, regulatory milestones, and competitive landscape to assess its long-term growth prospects. No analysts have issued buy or sell recommendations.
What are the main risks for ICCC?
The main risks for ImmuCell Corporation include regulatory hurdles for new products, particularly Re-Tain, which is critical to their growth strategy. Competition from larger animal health companies with greater resources poses a significant threat. Fluctuations in commodity prices and disease outbreaks in livestock populations can negatively impact demand for their products. The company's reliance on a limited number of key products also increases its vulnerability to market changes and competitive pressures. Managing these risks is crucial for ImmuCell's long-term success.
What are the key factors to evaluate for ICCC?
ImmuCell Corporation (ICCC) holds an AI score of 40/100 (low). Not financial advice.
How frequently does ICCC data refresh on this page?
ICCC prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven ICCC's recent stock price performance?
ImmuCell Corporation (ICCC) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Specialized expertise in dairy and beef cattle health. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider ICCC overvalued or undervalued right now?
Valuing ImmuCell Corporation (ICCC) requires multiple metrics. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
What research should beginners do before buying ICCC?
Before investing in ImmuCell Corporation (ICCC), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Limited analyst coverage may affect the accuracy of market sentiment analysis.
- Future regulatory outcomes are uncertain and could impact financial projections.